Viewing Study NCT02567669


Ignite Creation Date: 2025-12-24 @ 11:03 PM
Ignite Modification Date: 2025-12-30 @ 7:37 PM
Study NCT ID: NCT02567669
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-02-25
First Post: 2015-09-30
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Muscle Loss and Fatigue as a Consequence of Radiotherapy
Sponsor: Essentia Health
Organization:

Study Overview

Official Title: Muscle Loss and Fatigue as a Consequence of Radiotherapy
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2025-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: MUSFAT
Brief Summary: This study examines the extent of systemic muscle loss and the degree of fatigue experienced by breast cancer patients undergoing radiotherapy. This study seeks to identify whether muscle loss occurs outside the radiation fields and if muscle loss is correlated with the degree of fatigue.
Detailed Description: This study uses a patient reported survey to assess fatigue prior to radiotherapy for breast cancer. Fatigue is measured again at the completion of radiation treatments and at one and three months following completion of radiation.

Muscle measurements are made outside the treatment area using ct scans prior to radiation treatment, at the completion of radiation treatment and at one and three months after radiation treatment. The degree of fatigue and changes in muscle will be assessed. Changes will be correlated to determine if muscle loss contributes to fatigue.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: